ID   NBLW-R
AC   CVCL_VJ91
DR   cancercelllines; CVCL_VJ91
DR   Cosmic; 2668033
DR   Wikidata; Q95992387
RX   PubMed=27888620;
CC   Sequence variation: Mutation; HGNC; HGNC:427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=27888620).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=27888620
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 28,30
ST   D3S1358: 14,16
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 14
ST   FGA: 22,23
ST   Penta D: 13
ST   Penta E: 13,14
ST   TH01: 7,8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C4827; Adrenal gland neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VJ90 ! NBLW
SX   Male
AG   1Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 10
//
RX   PubMed=27888620; DOI=10.18632/oncotarget.13541; PMCID=PMC5349989;
RA   Chen L.-D., Humphreys A., Turnbull L., Bellini A., Schleiermacher G.,
RA   Salwen H.R., Cohn S.L., Bown N., Tweddle D.A.;
RT   "Identification of different ALK mutations in a pair of neuroblastoma
RT   cell lines established at diagnosis and relapse.";
RL   Oncotarget 7:87301-87311(2016).
//